NewAmsterdam Pharma NAMS 2024 Corporate Presentation

NewAmsterdam Pharma presents obicetrapib, a once-daily oral CETP inhibitor designed to lower LDL cholesterol in patients not reaching treatment goals on statins alone. The presentation highlights Phase 2 and Phase 3 BROOKLYN trial data demonstrating 36-40% mean LDL-C reduction as monotherapy and 58% reduction in combination with ezetimibe.